The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

• Conditions: Antiphospholipid Syndrome; Endothelial Dysfunction; Gout; Hyperuricemia; Metabolic Syndrome

• Registration Number: NCT01818505
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Detailed Description

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Patient eligibility：

1. Patients with gout

2. Patients with asymptomatic hyperuricemia

3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria： Patients younger than 20 years old

Study Timeline

• Study Start: 2013-03
• Study First Submitted: 2013-03-21
• Study First Submitted QC: 2013-03-25
• Study First Posted: 2013-03-26
• Status Verified: 2014-04
• Last Update Submitted: 2014-04-11
• Last Update Posted: 2014-04-14
• Primary Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

1. Patient with gouty arthritis
2. Patient with asymptomatic hyperurecemia
3. Patient of osteoarthritis but without hyperuricemia and gout

Read More

Exclusion Criteria

1.Patient younger than 20 y/o.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
development of metabolic syndrome or cardiovascular events	36 months

Secondary Outcome Measures

Name	Time	Method
Acute myocardial infarct or stroke	36 months or more

Trial Locations

Locations (1)

National Taiwan University Hospital Yun-Lin Branch; 🇨🇳 Dou-Liou City, Yun-Lin County, Taiwan